NEU

0.26%

$15.57 neuren pharmaceuticals limited

I'd guess that's our stumbling block to a deal. Was the Ph2 data...

First 62 Last

Share
Profile

Follow
mickqld

2,148 Posts.

40

08/03/18

13:47

Post #: 31619731
Share

Originally posted by TripAces ↑

Hottod i emailed Joe and asked his thoughts on whether Big Pharma cash repatriation will/is leading to premium deal prices. I also mentioned my interest in NEU and his comments are below for those interested:

Thanks for your note and interest in my presentation.

It’s a bit early to see the true effect of the tax and financial law changes in the US. However, I feel it’s safe to say it will materially increase investment by US-based large pharma companies. They might be willing to up the ante on deal value a bit. But, a more likely (and more immediate) result will be for deal values to continue the steady upward growth we’ve had for years; with pharma doing more deals per year on average. Most larger pharmas know value is value when it comes to external assets; and higher bank account balances don’t usually make them think they have to pay more for the same asset. I don’t think the increased deal volume will have a near-term direct effect of driving up deal values.

As far as Neuren, I’d have to take a closer look to say much definitively. At first blush, I’d say they’re 1) targeting indications of significant partner interest, and 2) are targeting indications with historically high failure rates for drugs in development. These two work against each other in partnering. I’d look more closely at competing drugs in development using the IGF-1 pathway and those with different MOAs. Also, I’d want to compare the Neuren’s PII efficacy data to end points desired by partners. Do partners have better choices out there? Is their data good enough to do a deal now, or would a partner be wise to wait for better data with this asset or watch for a different MOA to generate data?

Hope that helps some……….

Expand

I'd guess that's our stumbling block to a deal. Was the Ph2 data enough to push thru a deal or does big pharma have the luxury to wait on better data or someone else with something better ??

NEU Price at posting: $3.10 Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Bitcoin: Current State of Play & Where to Next | Swyftx

Emerald & Azure score Digger & Dealer awards

SVL

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

IMD

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

ARD

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

M2R

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

VTM

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

WNX

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

EQR

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

There are more pages in this discussion • 21 more messages in this thread...

First 62 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $15.57		Change -0.040(0.26%)		Mkt cap ! $1.990B

Open	High	Low	Value	Volume
$15.83	$15.87	$15.20	$8.124M	524.8K

Buyers (Bids)

No.	Vol.	Price($)
1	64	$15.49

Sellers (Offers)

Price($)	Vol.	No.
$15.58	597	1

View Market Depth

No.	Vol.	Price($)
1	64	15.490
1	226	15.400
1	500	15.320
1	745	15.300
1	50	15.250

Price($)	Vol.	No.
15.590	1282	1
15.600	20	1
15.700	300	1
15.750	2000	1
15.760	168	1

Last trade - 16.10pm 16/08/2024 (20 minute delay)

NEU (ASX) Chart

I'd guess that's our stumbling block to a deal. Was the Ph2 data...

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Bitcoin: Current State of Play & Where to Next | Swyftx

Emerald & Azure score Digger & Dealer awards

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I'd guess that's our stumbling block to a deal. Was the Ph2 data...

Top Stories

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Bitcoin: Current State of Play & Where to Next | Swyftx

Emerald & Azure score Digger & Dealer awards

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News